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SM1. Overtime distribution of the number of individuals enrolled in the selected 
primary studies (PSs).  
The total number of patients enrolled in PSs each year were annotated and 
analyzed, in order to verify if the pattern of PS published articles (see Fig. 2c in the 
main article) also reflected the overtime distribution of the PS patient population 
receiving oral risperidone (oRISP) or oral olanzapine (oOLA) conventional tablets. 
The time-dependent distribution of the total number of individuals enrolled in 
PSs showed a rapid decline of new empirical data on oRISP+oOLA in the recent years 
(Fig. 1S). It should be noted that two clinical studies (Strom et al., 2011; Thomas et al., 
2010) were not included in the regression curve analysis. These exceptionally large 
clinical studies focusing on the safety of sertindole and ziprasidone did not appear to 
be statistically representative of the oRISP+oOLA research pattern, since they 
accomplish Tukey’s fences criterion for “far out outliers”, i.e.  x ≥ Q3 + 3(Q3-Q1) 
(Cohen et al., 2003; Draper and Smith, 1998). 
 
Fig. 1S - The graph depicts the time-dependent distribution of the total number of 
individuals enrolled in published primary studies (PSs) which investigated the clinical 
properties of oRISP+oOLA (filled circles (●) symbol). 
Crossed circle () symbol shows the outlier values not included in the regression curve 
analysis. 
 
SM2. Comparison of the downward trends shown by industrial supported (IS) vs. 
independent research (IndR) studies in the last 9 years (2009-2017).  
Simple linear regression models of the number of published research articles 
investigating the clinical properties of oRISP+oOLA were used in order to highlight 
possible differences in the downward pattern shown by IS and IndR published articles 
over the last 9 years (2009-2017). With this purpose in mind, Shapiro-Wilk normality 
test (alpha level = 0.05) was applied in order to verify whether IS and IndR data (2009-
2017) came from normally distributed populations (Rahman and Govidarajulu, 1997; 
Shapiro and Wilk, 1965). Then, the statistical difference between the linear regressions 
coming from IndR vs. IS data was analyzed using two statistical approaches. Firstly, a 
two-tail t-Test (alpha level = 0.05) was applied in order to compare a possible statistical 
difference between the linear regression slopes of the two groups. Moreover, the 
reciprocal time-dependent distribution of the number of IndR vs. IS published articles 
was analyzed using point to point comparisons of predicted values of the two model 
solutions (Cohen et al., 2003; Draper and Smith, 1998).  
The statistical analyses indicated that the linear regression slopes of both IndR 
and IS were significantly different from 0 (IndR: b= -1.3833, S.E.= 0.3803, t= -3.638, p< 
0.01; IS: b= -4.4500, S.E.=0.6359, t= -6.998, p<0.001) (Fig. 2S), when the number of 
articles published between 2009 and 2017 were considered. Shapiro analyses 
confirmed the normality of IndR and IS data distribution (IndR: W= 0.88524, p= 0.1781; 
IS: W= 0.87891, p= 0.1529). A significant difference was found when the linear 
regression slopes of IndR and IS were compared using a t-test procedure (t= - 8.911, 
p<0.001) (Fig. 2S). This finding was consistent with the results of the point-to-point 
analysis of the predicted values, remarking the crossover of the two regression lines 
(Fig. 2S). Indeed, the number of IndR articles was lower than that of IS when analyzed 
between 2009 and 2011 (p<0.05). Subsequently, a comparable number of IndR and IS 
articles could be observed during 2012 and 2013 (p>0.05), while the number of IndR 
articles became higher than that of IS after 2014 (p<0.05). 
 Fig. 2S - The graph depicts the linear regression slopes ± C.I. of the number of IndR and 
IS articles which had been published between 2009 and 2017. 
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Abbreviation Definition 
   
       
 
oOLA Oral olanzapine  
   
       
 
oRISP  Oral risperidone  
   
       
 
PSs Primary studies  
   
       
 
SAs Secondary/adjunctive analyses 
 
       
 
IS Industrial supported 
  
       
 
IndR  Independent research 
  
       
 
ND Not declared 
   
       
 
MC Manufacturer/selling company 
 
       
 
CC Competitor company 
  
       
 
OthCs  Other competitors 
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